Self-administered Hyperinsufflation Chest on the Risk of Low Respiratory Infection in Patients With Multiple Sclerosis With Sputum Capacity Deficit

NCT ID: NCT04563832

Last Updated: 2022-04-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

84 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-25

Study Completion Date

2022-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In patients with neuromuscular disease, chest mobilization by hyperinsufflation slows respiratory decline by almost 80% compared to controls, and prevents complications like pneumonia, atelectasis and respiratory distress.

This insufflation technique improves the airway clearance and reduces the need for invasive ventilation. It also improves CV and DEPtoux in patients with neuromuscular pathology

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

During multiple sclerosis (MS), although expiratory involvement and reduced sputum capacity are predominant, automated techniques of hyperinsufflation and in-exsufflation remain underused and undervalued. A single retrospective study suggests a decrease in the decline in respiratory function with regular manual hyperinsufflation.

Evidence of a benefit of chest mobilization by hyperinsufflation by a controlled trial is therefore necessary before recommending its use in MS.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

* Control group: standardized respiratory management.
* Experimental group: same program, associated with the daily use of a hyperinsufflation technique.
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

standardized respiratory management.

Group Type OTHER

Standardized respiratory management program

Intervention Type OTHER

Bronchial decluttering education, respiratory physiotherapy, specialized medical follow-up for 2 years

Experimental group

same program as control group associated with the daily use of a hyperinsufflation technique (2 times per day during15 minutes, 5 days a week, for 2 years)

Group Type EXPERIMENTAL

Standardized respiratory management program

Intervention Type OTHER

Bronchial decluttering education, respiratory physiotherapy, specialized medical follow-up for 2 years

CoughAssist

Intervention Type OTHER

self-administered mechanical in-exsufflation - CoughAssist (2 x 15 min per day, 5 days per week for 2 years)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standardized respiratory management program

Bronchial decluttering education, respiratory physiotherapy, specialized medical follow-up for 2 years

Intervention Type OTHER

CoughAssist

self-administered mechanical in-exsufflation - CoughAssist (2 x 15 min per day, 5 days per week for 2 years)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed MS diagnosis (McDonald criteria)
* EDSS ≥ 7
* Age greater than or equal to 18 years.
* Expiratory flow during a coughing effort (DEPtoux) ˂4.5L / s.

Exclusion Criteria

* ENT and / or thoracic surgery less than 6 months old
* Progressive or past pneumothorax / pneumomediastinum
* Severe swallowing disorders.
* Inability to use the device under study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital Raymond Poincaré

Garches, Haut de Seine, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jonathan LEVY, Dr

Role: CONTACT

+33 147107900

Hélène PRIGENT, Pr

Role: CONTACT

+33 147107900

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jonathan LEVY, Dr

Role: primary

01.4710.70.60

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

APHP2020

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Dyspnea Self-Management: Internet or Face-to-Face
NCT00461162 COMPLETED PHASE1/PHASE2